NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one ...
Oblenio has begun dosing patients in its phase 1a first‑in‑human trial of LBL‑051, a tri‑specific T cell engager designed to ...
BeOne Medicines has been awarded an Innovation Passport for its investigational bispecific antibody BGB‑B2033, marking a significant step in the company’s plans to advance new treatment options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results